Uses of the drug Conjupri

Conjupri contains the active ingredient Levoamlodipine, a calcium channel blocker used to treat high blood pressure. So what are the uses, doses and precautions when using Conjupri?

Conjupri contains the active ingredient Levamlodipine, an active isomer of Amlodipine. This is a drug in the group of calcium channel blockers, which work to dilate blood vessels and improve blood flow. Conjupri is used to treat high blood pressure in adults and children who are at least 6 years old. Lowering blood pressure can reduce the risk of stroke and heart attack.

For the treatment of hypertension, Conjupri is indicated as monotherapy or in combination with other antihypertensive agents for hypertension. The initial dose is 2.5mg per day, which can be increased to 5mg per day. Small, emaciated, elderly or hepatically impaired patients may be initiated at 1.25 mg daily and this dose may be used in addition to other antihypertensive therapy. Then adjust the dosage according to the patient's blood pressure goal. Patients with renal impairment: No dose adjustment of Conjupri is required as the pharmacokinetics of the drug are not significantly affected.

Patients using Conjupri drug may experience undesirable effects including:
Common: Whole body: Ankle edema, facial flushing and feeling of heat, headache, dizziness, fatigue, depression weakness. Circulatory: Palpitations. Central Nervous System: Cramps. Gastrointestinal: Nausea, vomiting, abdominal pain, dyspepsia. Respiratory: Difficulty breathing. Uncommon: Circulatory: Excessive hypotension, tachycardia, chest pain. Skin: Rash, itching. Muscles, bones: Muscle pain, joint pain. Psychiatry: Sleep disturbance. Rare: Circulatory: Extrasystoles. Digestion: Hyperplasia of the gums. Skin: Urticaria. Liver: Increased liver enzymes Metabolism: Increased blood glucose. Mental: Confusion. Immunity: Erythema multiforme.

To ensure safety when using Conjupri, patients should note the following issues:
Patients should not use Conjupri if they are allergic to the ingredients in the drug. Patients may experience symptomatic hypotension, especially in patients with severe aortic stenosis, so a low dose should be started and the dose increased gradually. The drug is extensively metabolized in the liver. The plasma half-life is 56 hours in patients with impaired liver function. Therefore, caution should be exercised when using the drug for these subjects. Patients can take Conjupri with or without food. Blood pressure should be regularly monitored to control the disease well as well as to prevent hypotensive side effects. Chest pain may get worse when you first start taking Conjupri or when the dose is increased. Contact your doctor if chest pain becomes severe or persistent. Conjupri is only part of a complete program of treatment. Other therapies may include diet, exercise, weight control, and other medications. Follow a strict daily diet, medication and exercise routine. Use all blood pressure medications as directed and read all medication instructions carefully. Do not change your dose or stop taking it without your doctor's advice. Store Conjupri at room temperature away from moisture, heat and light Pregnant women: There are limited data on the use of the drug in pregnant women, so caution should be taken when using Conjupri during pregnancy. Lactation: Data from a published clinical study reported that Amlodipine was present in moderate concentrations in breast milk and that no adverse effects of Amlodipine in the breastfed infant were observed. .

Drug interactions can affect the effectiveness of treatment or increase unwanted effects. Ideally, patients should inform their doctor or pharmacist of all prescription and over-the-counter medicines, dietary supplements and vitamins they are taking for advice. Here are some interactions to watch out for when using Conjupri:
Levoamlodipine is a CYP3A4 substrate, so it may be affected by other drugs that affect this enzyme. Co-administration of Conjupri with moderate or strong CYP3A inhibitors leads to increased blood concentrations and may require dose reduction. Monitor for symptoms of hypotension and edema when Conjupri is co-administered with CYP3A inhibitors. There is no information on the effect of CYP3A inducers on Conjupri. Blood pressure should be closely monitored when Conjupri is administered with CYP3A inducers. Monitor for hypotension when Conjupri is co-administered with Sildenafil. Co-administration of Simvastatin with Conjupri increases the systemic exposure of Simvastatin. The dose of Simvastatin should be limited in this case to 20 mg/day. Conjupri may increase the concentration of Cyclosporin or Tacrolimus when taken together; Regularly monitor the blood levels of Cyclosporine and Tacrolimus and adjust the dose as appropriate. The article has provided an overview of the drug Conjupri. The information above is not a substitute for medical professional advice. Therefore, patients should consult their doctor or pharmacist before taking the drug.